ORGN 667 |
| Inhibition of dipeptidyl peptidase IV (DPP-IV), an enzyme that rapidly inactivates GLP-1, has been shown to increase the secretion of insulin and effectively regulate elevated blood glucose levels. Takeda San Diego has developed several novel series of compounds as inhibitors of DPP-IV for the treatment of type 2 diabetes. Multiple compounds are currently being evaluated in clinical trials, including SYR-322, which has progressed to Phase III. The role of a structure-based approach in the design and synthesis of highly potent and selective non-covalent DPP-IV inhibitors will be presented. |
|
Technical Achievements in Organic Chemistry Awards
1:40 PM-4:55 PM, Wednesday, 13 September 2006 Moscone Center -- Room 135, Oral
Division of Organic Chemistry |